Pancreatic Cancer Research

ResearcherUniversity of MiamiNo recent work listed

Caio Rocha‐Lima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2004-9202; OpenAlex author ID A5006553031, A5041409165. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2012: 3 papers · 2013: 3 papers · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper

Papers 9

  1. A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Pat… Co-author DOI 10.1089/pancan.2019.0012↗
  2. Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jvir.2016.10.023↗
  3. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Last author DOI 10.1007/s00280-014-2414-z↗
  4. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. Co-author DOI 10.1007/s11605-012-2064-6↗
  5. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic canc… Co-author DOI 10.1093/annonc/mdt066↗
  6. Pancreatic cancer clusters and arsenic-contaminated drinking water wells in Florida. Co-author DOI 10.1186/1471-2407-13-111↗
  7. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic panc… Co-author DOI 10.1093/annonc/mds142↗
  8. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Last author DOI 10.1097/coc.0b013e31821862fb↗
  9. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. Last author DOI 10.1186/1471-2407-12-199↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jaime Rafael Merchan · 4 shared papers, 2012–2017 · strength 0.16
  2. Jessica MacIntyre · 3 shared papers, 2012–2014 · strength 0.10
  3. Govindarajan Narayanan · 2 shared papers, 2012–2017 · strength 0.09
  4. Peter J. Hosein · 2 shared papers, 2012–2017 · strength 0.09
  5. Chrystal Ursula Louis · 1 shared paper, 2019 · strength 0.09
  6. Aparna Kalyan · 1 shared paper, 2019 · strength 0.09
  7. Allyson J. Ocean · 1 shared paper, 2019 · strength 0.09
  8. Muhammad Wasif Saif · 1 shared paper, 2019 · strength 0.09
  9. Diane M. Simeone · 1 shared paper, 2019 · strength 0.09
  10. Vaibhav Sahai · 1 shared paper, 2019 · strength 0.09
  11. Vincent J. Picozzi · 1 shared paper, 2019 · strength 0.09
  12. Philip A. Philip · 1 shared paper, 2019 · strength 0.09
  13. Gilberto De Lima Lopes Jr. · 2 shared papers, 2012–2014 · strength 0.07
  14. Howard P. Safran · 2 shared papers, 2012–2013 · strength 0.06
  15. Jose M. Yrizarry · 1 shared paper, 2017 · strength 0.06
  16. Hester J. Scheffer · 1 shared paper, 2017 · strength 0.06
  17. Riccardo Antonio Lencioni · 1 shared paper, 2017 · strength 0.06
  18. Wen Liu‐Mares · 1 shared paper, 2013 · strength 0.04
  19. David J. Lee · 1 shared paper, 2013 · strength 0.04
  20. Soley Bayraktar · 1 shared paper, 2014 · strength 0.04
  21. Heloisa Prado Soares · 1 shared paper, 2014 · strength 0.04
  22. Marina Talamonti · 1 shared paper, 2013 · strength 0.03
  23. Smitha Krishnamurthi · 1 shared paper, 2013 · strength 0.03
  24. William C. Small · 1 shared paper, 2013 · strength 0.03
  25. Jeffrey M. Hardacre · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.